Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

ClinicalTrials.gov ID: NCT02227862

Public ClinicalTrials.gov record NCT02227862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Randomized, Multi-Center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (based on change in HbA1c from baseline to 24 weeks) when administered in combination with mealtime insulin lispro.

Study identification

NCT ID
NCT02227862
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Mylan Inc.
Industry
Enrollment
558 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2014 (Actual)
Primary completion
Jul 2016 (Actual)
Completion
Jul 2016 (Actual)
Last update posted
Mar 3, 2022

2014 – 2016

United States locations

U.S. sites
72
U.S. states
22
U.S. cities
67
Facility City State ZIP Site status
Mylan Investigational Site Bell Gardens California 90201 —
Mylan Investigational Site Fresno California 93720 —
Mylan Investigational Site Greenbrae California 93720 —
Mylan Investigational Site La Jolla California 92037 —
Mylan Investigational Site La Mesa California 91942 —
Mylan Investigational Site Long Beach California 90807 —
Mylan Investigational Site Los Gatos California 95032 —
Mylan Investigational Site Mission Hills California 91345 —
Mylan Investigational Site National City California 91950 —
Mylan Investigational Site Northridge California 91324 —
Mylan Investigational Site Tustin California 92780 —
Mylan Investigational Site Walnut Creek California 94598 —
Mylan Investigational Site Bradenton Florida 34208 —
Mylan Investigational Site Cooper City Florida 33024 —
Mylan Investigational Site Hialeah Florida 33012 —
Mylan Investigational Site Hollywood Florida 33021 —
Mylan Investigational Site Miami Florida 33142 —
Mylan Investigational Site Miami Florida 33156 —
Mylan Investigational Site New Port Richey Florida 34652 —
Mylan Investigational Site Palm Harbor Florida 34684 —
Mylan Investigational Site West Palm Beach Florida 33401 —
Mylan Investigational Site Atlanta Georgia 30318 —
Mylan Investigational Site Columbus Georgia 31904 —
Mylan Investigational Site Honolulu Hawaii 96814 —
Mylan Investigational Site Idaho Falls Idaho 83404 —
Mylan Investigational Site Crystal Lake Illinois 60012 —
Mylan Investigational Site LaGrange Illinois 60525 —
Mylan Investigational Site Springfield Illinois 62704 —
Mylan Investigational Site Anderson Indiana 46011 —
Mylan Investigational Site Muncie Indiana 47304 —
Mylan Investigational Site Council Bluffs Iowa 51501 —
Mylan Investigational Site Des Moines Iowa 50314 —
Mylan Investigational Site Overland Park Kansas 66210 —
Mylan Investigational Site Topeka Kansas 66606 —
Mylan Investigational Site Lexington Kentucky 40503 —
Mylan Investigational Site Billings Montana 59101 —
Mylan Investigational Site Omaha Nebraska 68114 —
Mylan Investigational Site Omaha Nebraska 68131 —
Mylan Investigational Site Las Vegas Nevada 89128 —
Mylan Investigational Site Albany New York 12206 —
Mylan Investigational Site Mineola New York 11501 —
Mylan Investigational Site Staten Island New York 10301 —
Mylan Investigational Site Syracuse New York 13210 —
Mylan Investigational Site Asheville North Carolina 28803 —
Mylan Investigational Site Burlington North Carolina 27215 —
Mylan Investigational Site Greensboro North Carolina 27408 —
Mylan Investigational Site Greenville North Carolina 27834 —
Mylan Investigational Site Hickory North Carolina 28601 —
Mylan Investigational Site Morehead City North Carolina 28557 —
Mylan Investigational Site Wilmington North Carolina 28401 —
Mylan Investigational Site Cincinnati Ohio 45236 —
Mylan Investigational Site Mentor Ohio 44060 —
Mylan Investigational Site Bend Oregon 97701 —
Mylan Investigational Site Corvallis Oregon 97330 —
Mylan Investigational Site Chattanooga Tennessee 37411 —
Mylan Investigational Site Memphis Tennessee 38119 —
Mylan Investigational Site Austin Texas 78731 —
Mylan Investigational Site Dallas Texas 75231 —
Mylan Investigational Site El Paso Texas 79925 —
Mylan Investigational Site Round Rock Texas 78681 —
Texas Diabetes & Endocrinology Round Rock Texas 78681 —
Mylan Investigational Site San Antonio Texas 78258 —
Mylan Investigational Site Ogden Utah 84405 —
Mylan Investigational Site Salt Lake City Utah 84102 —
Mylan Investigational Site Salt Lake City Utah 84109 —
Mylan Investigational Site Salt Lake City Utah 84121 —
Mylan Investigational Site South Jordan Utah 84095 —
Mylan Investigational Site Chesapeake Virginia 23321 —
Mylan Investigational Site Manassas Virginia 20110 —
Mylan Investigational Site Renton Washington 98057 —
Mylan Investigational Site Tacoma Washington 98405 —
Mylan Investigational Site Vancouver Washington 98664 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02227862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 3, 2022 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02227862 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →